Table 5.
Outcomes of the cardiac/muscular irAEs according to immunosuppressive treatments and according to best overall tumor response among patients with available treatment and tumor response data based on RECIST
| N | Complete remission, n | Partial remission, n | Neither improvement nor death, n | Death, n | Not reported, n | |
|---|---|---|---|---|---|---|
| CTS treatment plus other agents | 55 | 19 | 6 | 2 | 27 | 1 |
| Only CTS | 59 | 24 | 13 | 2 | 20 | 0 |
| CTS ≤ 1 mg/kg | 35 | 13 | 8 | 2 | 12 | 0 |
| CTS >1 and <2 mg/kg | 23 | 9 | 5 | 1 | 8 | 0 |
| CTS ≥ 2 mg/kg | 39 | 14 | 5 | 0 | 20 | 0 |
| Biologic immunosuppressant | 8 | 1 | 2 | 0 | 5 | 0 |
| DMARDS | 14 | 8 | 1 | 0 | 5 | 0 |
| IVIG | 32 | 12 | 3 | 1 | 16 | 0 |
| Plasma exchange | 16 | 2 | 1 | 1 | 11 | 1 |
| Complete response | 6 | 3 | 1 | 0 | 2 | 0 |
| Partial response | 23 | 11 | 7 | 0 | 5 | 0 |
| Stable disease | 15 | 8 | 3 | 0 | 4 | 0 |
| Progressive disease | 15 | 6 | 1 | 1 | 6 | 1 |
CTS, corticosteroids; DMARD, disease-modifying antirheumatic drug; irAEs, immune-related adverse events; IVIG, intravenous immunoglobulin.